Form 8-K - Current report:
SEC Accession No. 0001641172-25-014972
Filing Date
2025-06-13
Accepted
2025-06-13 08:15:17
Documents
18
Period of Report
2025-06-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 63772
2 EX-10.1 ex10-1.htm EX-10.1 255351
3 EX-10.2 ex10-2.htm EX-10.2 70101
4 EX-10.3 ex10-3.htm EX-10.3 113211
5 EX-10.4 ex10-4.htm EX-10.4 101443
6 EX-99.1 ex99-1.htm EX-99.1 15724
7 GRAPHIC ex99-1_001.jpg GRAPHIC 4965
  Complete submission text file 0001641172-25-014972.txt   911057

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE indp-20250612.xsd EX-101.SCH 3020
9 XBRL LABEL FILE indp-20250612_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE indp-20250612_pre.xml EX-101.PRE 22362
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3619
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40652 | Film No.: 251044788
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)